| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00451035 Details | 2021-07-15 Interventional | 2 | [1 Refs] | 29 | Panobinostat Leukemia Leukemia, Myelo… Leukemia, Myelo… Chronic Myeloid… | - - | ||
| NCT00449761 Details | 2021-07-15 Interventional | 2 | [1 Refs] | 27 | Panobinostat Blast Crisis Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… | - - | ||
| NCT00445068 Details | 2021-07-14 Interventional | 2 | 38 | Panobinostat Multiple Myelom… Neoplasms, Plas… | - - | |||
| NCT03200600 Details | 2021-07-13 Interventional | 4 | 126 | BB 1101 Dexamethasone Dexamethasone 2… Dexamethasone a… Flurbiprofen Flurbiprofen ax… Carcinoma, Non-… Delirium Dexamethasone Flubiprofen Axe… Surgery--Compli… | Protocol violation occurred frequently during the postoperative period. - | |||
| NCT03231397 Details | 2021-07-09 Interventional | 4 | 2 | Fluorodeoxygluc… Aneurysm Aortic Aneurysm Aortic Aneurysm… Rupture Abdominal Aorti… | We were unable to recruit more subjects who met the inclusion/exclusion criteria and we have
closed the study. - | |||
| NCT01395953 Details | 2021-07-09 Interventional | 2 | 0 | Buspirone Autism Spectrum… Autistic Disord… Child Developme… Autism Spectrum… | This study was withdrawn due to competing research interests and slow recruitment. - | |||
| NCT00001962 Details | 2021-07-09 Interventional | 2 | 100 | Daclizumab Anemia Anemia, Aplasti… Anemia, Diamond… Red-Cell Aplasi… Aplastic Anemia Diamond Blackfa… Pure Red Cell A… | DSMB recommended closing the study and publishing the results - | |||
| NCT04955262 Details | 2021-07-08 Interventional | 1 | 0 | Nivolumab Melanoma Metastatic Mela… | Did not initiate due to business reasons. IND is inactive. - | |||
| NCT03802227 Details | 2021-07-08 Interventional | 1 | 8 | Oxycodone Chronic Pain Moderate to Sev… | Sponsor Decision The study was originally planned for 24 patients. However enrollment was stopped due to the CDP being stopped at 8 and therefore limits the generalizability of this data. | |||
| NCT03040024 Details | 2021-07-08 Interventional | 4 | 71 | Ketamine Delirium Otolaryngeal Ca… | Halted due to COVID 19; we believe we have adequate data for analysis - | |||
| NCT02565511 2015-002715-15 Details | 2021-07-08 Interventional | 2/3 | 480 | Umibecestat Alzheimer Disea… Alzheimers Dise… | - The study was terminated due to unexpected changes in cognitive function, brain volume loss, and body weight loss. Cohort II (CNP520) treatment was stopped and evaluated through an off-treatment follow-up period. After the decision to terminate Cohort II of the study (CNP520), treatment with CAD106 (Cohort I) was also terminated | |||
| NCT01784861 Details | 2021-07-08 Interventional | 1/2 | 23 | Everolimus Neuroendocrine … Pancreatic Neop… Adenocarcinoma | Pharmaceutical company decision - | |||
| NCT01070888 Details | 2021-07-07 Interventional | 4 | 6 | Budesonide Formoterol Fuma… Asthma Asthma, Exercis… Exercise Induce… | Unable to reach target goal - | |||
| NCT02440568 Details | 2021-07-06 Interventional | 1/2 | 22 | Cytarabine Homoharringtoni… Idarubicin Acute Myeloid L… | - - | |||
| NCT04946162 Details | 2021-07-02 Interventional | 4 | 0 | Tadalafil Pneumonia Respiratory Dis… ARDS, Human COVID Sars-CoV2 | The investigators never completed the IRB application due to decrease in need to conduct the
study. - | |||
| NCT01919190 Details | 2021-07-02 Interventional | 4 | 67 | Bupivacaine Pain | Due to reasons unrelated to safety; primary endpoint signal seen during pre-specified interim
analysis. - | |||
| NCT03730402 Details | 2021-07-01 Interventional | 4 | 34 | Bupivacaine Opioid Use | There were not enough attendings/residents working on the study throughout the COVID-19
pandemic in order to enroll the number of patients required to meet statistical significance. - | |||
| NCT03639779 Details | 2021-07-01 Interventional | 4 | 5 | Sodium thiosulf… Calcinosis Calcinosis Cuti… | Time and resource constraints The study had to be closed early due to lack up support/resources. | |||
| NCT04655183 Details | 2021-06-30 Interventional | 1/2 | 0 | Niraparib Breast Neoplasm… Advanced Solid … Breast Cancer | Trial withdrawn based on portfolio prioritization; oral ATRi M1774 in combination with
niraparib is under investigation in DDRiver Solid Tumor 301 - | |||
| NCT03854396 Details | 2021-06-30 Interventional | 3 | 0 | Dehydroepiandro… Communicable Di… Infections Recurrence Syndrome Urinary Tract I… Menopause Postmenopausal … Postmenopausal … Postmenopause Recurrent Urina… | due to termination of ISR by PI with agreement by grant sponsor - |